Holen Sie sich die Stockscreener-App
1.95
8.94%
0.16
Handel nachbörslich:
1.92
-0.03
-1.54%
Schlusskurs vom Vortag:
$1.79
Offen:
$1.72
24-Stunden-Volumen:
1.49M
Relative Volume:
0.98
Marktkapitalisierung:
$181.36M
Einnahmen:
$34.48M
Nettoeinkommen (Verlust:
$-102.07M
KGV:
-1.3356
EPS:
-1.46
Netto-Cashflow:
$-104.90M
1W Leistung:
+3.72%
1M Leistung:
+19.63%
6M Leistung:
+48.85%
1J Leistung:
+4.84%
1-Tages-Spanne:
$1.6203
$1.95
1-Wochen-Bereich:
$1.6203
$1.95
52-Wochen-Spanne:
$0.66
$2.9995
Caribou Biosciences Inc Stock (CRBU) Company Profile
Firmenname
Caribou Biosciences Inc
Sektor
Branche
Telefon
510-982-6030
Adresse
2929 7TH STREET, SUITE 105, BERKELEY
Vergleichen Sie CRBU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.95 | 166.48M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Eingeleitet | Evercore ISI | Outperform |
| 2023-07-11 | Eingeleitet | Truist | Buy |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-17 | Eingeleitet | BofA Securities | Buy |
| 2021-08-17 | Eingeleitet | Citigroup | Neutral |
| 2021-08-17 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Caribou Biosciences Inc Aktie (CRBU) Neueste Nachrichten
Caribou Biosciences Reports Increased Losses Amid R&D Efforts - TipRanks
Navigating the Storm: Caribou Biosciences' Strategic Rebalancing and the Road to Gene-Editing Dominance - AInvest
Caribou Biosciences earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Caribou Biosciences Q2 2025: $184mln cash, H2 2027 funding, CB-010 & CB-011 data in H2 2025. - AInvest
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Stock Titan
Is Caribou Biosciences Inc. Forming a Consolidation BaseTrade Setups With Clear Risk Limits Highlighted - beatles.ru
Caribou Biosciences CRBU Q2 2025 Earnings Preview Downside Risk Amid Clinical Trial Delays - AInvest
Sentiment Tools Show Shift in Trader Mood on Caribou Biosciences Inc.Exit Ready Momentum Stock Watchlist Expanded - beatles.ru
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU - ACCESS Newswire
Caribou Biosciences Inc. Price Targets Raised After ReboundWeekly Hot Picks With Buy Confidence Released - metal.it
What analysts say about Caribou Biosciences Inc. stockInvest confidently with professional advice - Jammu Links News
Caribou Biosciences Inc. Stock Analysis and ForecastTremendous growth potential - Jammu Links News
What makes Caribou Biosciences Inc. stock price move sharplyMaximize your returns with smart trade entries - Jammu Links News
Is Caribou Biosciences Inc. stock overvalued or undervaluedBuild wealth with steady, reliable stocks - Jammu Links News
What are the latest earnings results for Caribou Biosciences Inc.Achieve consistent double-digit growth rates - Jammu Links News
How does Caribou Biosciences Inc. compare to its industry peersBuild wealth steadily with expert advice - Jammu Links News
Is it the right time to buy Caribou Biosciences Inc. stockAchieve breakthrough investment performance - Jammu Links News
How strong is Caribou Biosciences Inc. company’s balance sheetInvest in high-yield stocks with confidence - Jammu Links News
Caribou Biosciences Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Caribou Biosciences Inc. stock prediction for this weekPortfolio Diversification Stock Ideas From Experts - metal.it
How Interest Rate Changes Impact Caribou Biosciences Inc. Stock PerformanceLong Hold Safe Return Strategy Reviewed - metal.it
Why Caribou Biosciences Inc. stock attracts strong analyst attentionTechnical Entry Strategy for Beginners Explained - beatles.ru
How many analysts rate Caribou Biosciences Inc. as a “Buy”Earnings Report Entry Points For Fast Growth - Jammu Links News
Why is Caribou Biosciences Inc. stock attracting strong analyst attentionHigh-velocity gains - Jammu Links News
What institutional investors are buying Caribou Biosciences Inc. stockMaximize returns with strategic trading plans - Jammu Links News
What is Caribou Biosciences Inc. company’s growth strategyCapitalize on fast-growing investment opportunities - jammulinksnews.com
Published on: 2025-07-28 05:44:44 - Jammu Links News
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
What risks could impact Caribou Biosciences Inc. stock performanceExtraordinary profit generation - Jammu Links News
What drives Caribou Biosciences Inc. stock priceFree High-Return Strategy Alerts - Autocar Professional
Following a 1.3% Decline Over Last Year, Recent Gains May Please Caribou Biosciences, Inc. (NASDAQ:CRBU) Institutional Owners - 富途牛牛
Is Caribou Biosciences Inc. a good long term investmentDynamic profit opportunities - Autocar Professional
Finanzdaten der Caribou Biosciences Inc-Aktie (CRBU)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):